January 24, 2023

Blinatumomab significantly improves overall survival in newly diagnosed B-ALL patients who are MRD-negative after initial treatment (study E1910)

January 5, 2023

The Winter 2023 advocacy blog Considering Clinical Trials is now available

December 20, 2022

The November/December 2022 News from ECOG-ACRIN blog is now available

December 19, 2022

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

December 15, 2022

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

December 14, 2022

Blinatumomab further improves survival among patients with B-ALL and a good prognosis (study E1910)

December 13, 2022

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

December 13, 2022

HealthDay News informs the public of the 12-year TAILORx results

December 13, 2022

Blinatumomab regimen may lead to โ€˜diminishing use of transplantโ€™ for B-ALL subgroup (study E1910)

ECOG-ACRIN Cancer Research Group